This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
The Price of Time
Higher real yields are putting renewed pressure on early-stage biotech, increasing the appeal of China’s pipeline of drugs already in clinical development